Keybanc analyst Todd Thomas maintains WESCO International (NYSE:WCC) with a Overweight and lowers the price target from $165 to $150.
AstraZeneca Announced Danicopan As Add-on To Ultomiris Or Soliris Improved Haemoglobin Levels And Maintained Disease Control In Patients With PNH Experiencing Signs Of Clinically Significant Extravascular Haemolysis
Results from ALPHA Phase III trial demonstrated statistically significant increase compared to placebo in mean haemoglobin from baseline to week 12. All key secondary endpoints met statistical superiority, showing
